JP2024529452A - 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン - Google Patents

長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン Download PDF

Info

Publication number
JP2024529452A
JP2024529452A JP2024504971A JP2024504971A JP2024529452A JP 2024529452 A JP2024529452 A JP 2024529452A JP 2024504971 A JP2024504971 A JP 2024504971A JP 2024504971 A JP2024504971 A JP 2024504971A JP 2024529452 A JP2024529452 A JP 2024529452A
Authority
JP
Japan
Prior art keywords
agonist
compound
dose
patients
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529452A5 (https=
JPWO2023006923A5 (https=
Inventor
，ミヒャエル デシュ
ヘンニゲ，アニタ・マグダレナ
ショエルヒ，コリンナ・イザベル
ターマー，クラウス
バーグストランド，ジャン・ペル・マルティン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2024529452A publication Critical patent/JP2024529452A/ja
Publication of JP2024529452A5 publication Critical patent/JP2024529452A5/ja
Publication of JPWO2023006923A5 publication Critical patent/JPWO2023006923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024504971A 2021-07-30 2022-07-28 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン Pending JP2024529452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188741.9 2021-07-30
EP21188741 2021-07-30
PCT/EP2022/071281 WO2023006923A1 (en) 2021-07-30 2022-07-28 Dose regimen for long-acting glp1/glucagon receptor agonists

Publications (3)

Publication Number Publication Date
JP2024529452A true JP2024529452A (ja) 2024-08-06
JP2024529452A5 JP2024529452A5 (https=) 2025-07-30
JPWO2023006923A5 JPWO2023006923A5 (https=) 2025-07-30

Family

ID=77155646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504971A Pending JP2024529452A (ja) 2021-07-30 2022-07-28 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン

Country Status (10)

Country Link
US (1) US20250262279A1 (https=)
EP (1) EP4376871A1 (https=)
JP (1) JP2024529452A (https=)
KR (1) KR20240043778A (https=)
CN (1) CN117677395A (https=)
AU (1) AU2022320922A1 (https=)
CA (1) CA3226846A1 (https=)
CL (1) CL2024000222A1 (https=)
MX (1) MX2024001276A (https=)
WO (1) WO2023006923A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2019060660A1 (en) * 2017-09-25 2019-03-28 Merck Sharp & Dohme Corp. CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Also Published As

Publication number Publication date
WO2023006923A1 (en) 2023-02-02
CA3226846A1 (en) 2023-02-02
EP4376871A1 (en) 2024-06-05
AU2022320922A1 (en) 2024-01-18
MX2024001276A (es) 2024-02-15
KR20240043778A (ko) 2024-04-03
CL2024000222A1 (es) 2024-08-02
US20250262279A1 (en) 2025-08-21
CN117677395A (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
JP2024529452A (ja) 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン
Guo et al. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial
JP6823167B2 (ja) ミオスタチン阻害剤の使用および併用療法
Pivonello et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities
Brown et al. Management of the metabolic effects of HIV and HIV drugs
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
US20210186990A1 (en) Methods and compositions for treating various disorders
JP2008516955A (ja) 患者において薬物誘発性の有害な副作用を軽減する方法
Feeney et al. Insulin resistance in treated HIV infection
US20220265614A1 (en) Treatment comprising fxr agonists
Jordan et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients
Galindo et al. Insights into the mechanism of action of tirzepatide: A narrative review
WO2005049043A1 (en) Combination therapy comprising metformin and anticonvulsant agents
US20250177353A1 (en) Methods of treating mitochondria-related disorders
Dhillon Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
RU2664442C2 (ru) Способ снижения веса
Kang et al. The ultra-long acting LAPS GLP/GCG dual agonist, HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
Blondin et al. Human BAT thermogenesis is stimulated by the β 2-adrenergic receptor
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
US20250302798A1 (en) Sting inhibitors and use thereof
US20260007630A1 (en) Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
Nirmala Chapter-3 Tirzepatide: A Brand New Medication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250722